Phase 3 topline data for ULTOMIRIS® (ravulizumab) in aHUS presented at ERA-EDTA Congress
The topline Phase 3 results of ULTOMIRIS (ravulizumab) show efficacy and safety in treating aHUS. The therapy has shown promise in reducing inflammation and blood clotting, with the potential to treat patients with progressive organ damage.